Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELVN Enliven Therapeutics	$21.91 +11.4%	$18.30	$13.30 ▼ $30.03	$1.08B	0.79	285,750 shs	3.22 million shs
EPZM Epizyme	$1.47	$1.47	$0.41 ▼ $5.80	$247.44M	-0.41	3.23 million shs	7,960 shs
PAHC Phibro Animal Health	$23.93 -2.4%	$21.25	$16.16 ▼ $26.55	$969.98M	0.74	205,137 shs	152,026 shs
SNDX Syndax Pharmaceuticals	$10.25 -3.9%	$11.24	$8.58 ▼ $25.07	$881.98M	0.74	1.80 million shs	1.31 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELVN Enliven Therapeutics	+11.44%	+5.64%	+10.16%	+5.64%	-3.69%
EPZM Epizyme	0.00%	0.00%	0.00%	0.00%	0.00%
PAHC Phibro Animal Health	-2.37%	-0.62%	+2.44%	+12.61%	+34.59%
SNDX Syndax Pharmaceuticals	-3.94%	-10.48%	+10.45%	-20.85%	-49.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELVN Enliven Therapeutics	2.4769 of 5 stars	3.5	1.0	0.0	0.0	2.6	4.2	0.0
EPZM Epizyme	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	3.7505 of 5 stars	0.8	4.0	2.5	1.1	2.5	3.3	2.5
SNDX Syndax Pharmaceuticals	2.9368 of 5 stars	3.5	0.0	0.0	4.4	2.2	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELVN Enliven Therapeutics	3.00	Buy	$37.25	70.01% Upside
EPZM Epizyme	0.00	N/A	N/A	N/A
PAHC Phibro Animal Health	1.50	Reduce	$20.00	-16.42% Downside
SNDX Syndax Pharmaceuticals	2.91	Moderate Buy	$35.91	250.33% Upside

Current Analyst Ratings Breakdown

Latest EPZM, PAHC, ELVN, and SNDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	ELVN Enliven Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $27.00
5/15/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/8/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $21.00
5/6/2025	SNDX Syndax Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$16.00 ➝ $17.00
5/6/2025	SNDX Syndax Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/15/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$20.00
3/21/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $39.00
3/20/2025	SNDX Syndax Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$39.00 ➝ $41.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$5.97 per share	N/A
EPZM Epizyme	$37.43M	6.61	N/A	N/A	($0.54) per share	-2.72
PAHC Phibro Animal Health	$1.19B	0.81	$2.20 per share	10.87	$6.09 per share	3.93
SNDX Syndax Pharmaceuticals	$43.72M	20.17	N/A	N/A	$6.53 per share	1.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELVN Enliven Therapeutics	-$71.58M	-$1.92	N/A	N/A	N/A	N/A	-29.46%	-27.33%	8/12/2025 (Estimated)
EPZM Epizyme	-$251.12M	-$1.72	N/A	N/A	N/A	-391.90%	-2,459.33%	-69.74%	N/A
PAHC Phibro Animal Health	$2.42M	$0.78	49.85	11.40	0.45	1.75%	25.35%	6.21%	8/27/2025 (Estimated)
SNDX Syndax Pharmaceuticals	-$209.36M	-$3.86	N/A	N/A	N/A	N/A	-64.34%	-57.72%	8/7/2025 (Estimated)

Latest EPZM, PAHC, ELVN, and SNDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/5/2025	Q1 2025	SNDX Syndax Pharmaceuticals	-$1.04	-$0.98	+$0.06	-$0.98	$15.88 million	$20.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
EPZM Epizyme	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	2.01%	N/A	61.54%	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest EPZM, PAHC, ELVN, and SNDX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELVN Enliven Therapeutics	N/A	17.44	17.44
EPZM Epizyme	N/A	5.35	5.19
PAHC Phibro Animal Health	2.99	3.20	1.37
SNDX Syndax Pharmaceuticals	N/A	6.99	6.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELVN Enliven Therapeutics	95.08%
EPZM Epizyme	76.45%
PAHC Phibro Animal Health	99.34%
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ELVN Enliven Therapeutics	25.90%
EPZM Epizyme	23.40%
PAHC Phibro Animal Health	50.07%
SNDX Syndax Pharmaceuticals	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELVN Enliven Therapeutics	50	49.07 million	34.59 million	Optionable
EPZM Epizyme	250	168.33 million	128.97 million	Optionable
PAHC Phibro Animal Health	1,860	40.53 million	20.22 million	Optionable
SNDX Syndax Pharmaceuticals	110	86.05 million	81.86 million	Optionable

EPZM, PAHC, ELVN, and SNDX Headlines

Recent News About These Companies

Syndax reports publication of revumenib data from BEAT AML trial

June 13 at 11:25 AM | msn.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Assenagon Asset Management S.A.

June 13 at 4:35 AM | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.7% - Time to Sell?

June 12 at 2:47 PM | marketbeat.com

Syndax Pharma releases new data from its AUGMENT-101 trial of Revuforj

June 12 at 1:31 PM | thepharmaletter.com

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

June 12 at 12:02 PM | globenewswire.com

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

June 12 at 7:00 AM | globenewswire.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

June 7, 2025 | marketbeat.com

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

June 5, 2025 | globenewswire.com

Ameriprise Financial Inc. Has $423,000 Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

June 5, 2025 | marketbeat.com

Kura Posts New Data, Secures NDA Acceptance in Acute Myeloid Leukemia Race With Syndax

June 3, 2025 | biospace.com

Nuveen Asset Management LLC Trims Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

June 1, 2025 | marketbeat.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Bank of America Corp DE

June 1, 2025 | marketbeat.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Wellington Management Group LLP

May 31, 2025 | marketbeat.com

Voloridge Investment Management LLC Takes $1.05 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

May 31, 2025 | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 4.9% - Still a Buy?

May 30, 2025 | marketbeat.com

Syndax Announces Participation in June Investor Conferences

May 29, 2025 | globenewswire.com

Polar Asset Management Partners Inc. Invests $1.12 Million in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

May 29, 2025 | marketbeat.com

Millennium Management LLC Has $7.76 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

May 28, 2025 | marketbeat.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Brokerages

May 28, 2025 | marketbeat.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Two Sigma Investments LP

May 27, 2025 | marketbeat.com

Two Sigma Advisers LP Has $7.09 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

May 26, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPZM, PAHC, ELVN, and SNDX Company Descriptions

Enliven Therapeutics NASDAQ:ELVN

$21.91 +2.25 (+11.44%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$21.96 +0.05 (+0.25%)

As of 06/13/2025 06:44 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Epizyme NASDAQ:EPZM

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Phibro Animal Health NASDAQ:PAHC

$23.93 -0.58 (-2.37%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$23.25 -0.68 (-2.86%)

As of 06/13/2025 04:57 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Syndax Pharmaceuticals NASDAQ:SNDX

$10.25 -0.42 (-3.94%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$10.24 -0.01 (-0.10%)

As of 06/13/2025 04:31 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time